BMC Psychiatry最新文献

Objective: In recent years, there has been a rapid increase in reports upon social-cognition impairments in bipolar disorder. This study aimed to compare the characteristics of social cognition domains in bipolar I (BD I) and II (BD II) based on the findings to date.

Methods: A systematic literature search was conducted on Web of Science and PubMed from inception to 28 August 2024. Studies with all-age-group of ICD-10, DSM-IV, DSM-IV-TR, or DSM-5 defined BD (I or II) either in a remitted or symptomatic state were included. The risk of bias was measured using the Newcastle-Ottawa Scale, and the quality of the sources was evaluated using GRADE criteria. Results of the studies were measured by synthesizing Hedge's g effect sizes through a random effects meta-analytic approach.

Results: A total of 20 studies were included, covering three core domains of social cognition (theory of mind (ToM), emotion processing and attributions). There was no significant difference in ToM between BD I and BD II and in emotion processing between non-psychotic patients with BD I and BD II, and history of psychosis negatively predicted performance on emotion processing. Furthermore, BD II performed worse than BD I in attributions, with a low to moderate summary effect size.

Conclusions: BD I and BD II performed similarly on ToM and emotional processing, but BD II had more impaired attributions. Future studies are encouraged to control for the influence of clinical features, to use more neuroscientific techniques, and to explore on other domains of social cognition in bipolar subtypes.

Depression is one of the most common psychiatric conditions. Given its high prevalence and disease burden, accurate diagnostic procedures and valid instruments are warranted to identify those in need of treatment. The Patient Health Questionnaire-9 (PHQ-9) is one of the most widely used self-report measures of depression, and its validity and reliability has been evaluated in several languages. However, the Swedish translation has yet not been subject to psychometric evaluation, and no previous psychometric evaluation of the instrument have used both Rasch analysis and classic test theory. The aim of this study was to investigate validity and reliability of the PHQ-9 in a Swedish sample of individuals with self-reported current or past mental health problems using Rasch analysis and confirmatory factor analysis. A sample of 4958 participants was recruited from an online survey covering different aspects of covid-19 and mental health targeted towards individuals with mental health problems. Results showed that a one-factor solution fit the data after removing one item and that some items had a different response pattern for older respondents. Furthermore, after removing item 2 and merging the two middle response categories for item 9, the Swedish translation of PHQ-9 showed adequate psychometric properties. The findings suggests that the Swedish translation of PHQ-9 may need to be adapted in order to make adequate interpretations of an individual score and to differentiate between populations. Further tests of its validity and reliability in other Swedish samples are needed to fully understand the properties of the Swedish version of PHQ-9.

Objective: Autism spectrum disorder (ASD) is characterized by high rates of comorbidity with other mental disorders, including anxiety disorders and obsessive-compulsive disorder. Beyond a mere concept of comorbidity, recent literature is speculating the existence of a neurodevelopmental nature of such mental disorders. The aim of the study is to investigate the distribution of social-phobic, obsessive-compulsive and panic-agoraphobic traits within a sample of individuals with ASD, social anxiety disorder (SAD), obsessive-compulsive disorder (OCD) and panic disorder (PD).

Methods: 40 participants with ASD, 40 with SAD, 40 with OCD, 40 with PD and 50 HC were assessed with the Social Anxiety Spectrum-Short Version (SHY-SV) questionnaire, the Obsessive-Compulsive Spectrum-Short Version (OBS-SV) questionnaire and the Panic Agoraphobic Spectrum-Short Version (PAS-SV) questionnaire. Statistical analyses included Kruskal-Wallis test and Chi-square test.

Results: When analyzing SHY-SV scores, the SAD group obtained the highest scores, with individuals with ASD following closely, significantly surpassing the scores of the remaining diagnostic groups. In the examination of OBS-SV questionnaire scores, individuals with ASD once again secured the second-highest scores, trailing only the OCD group. These scores were notably higher than those of both the PD group and healthy controls. In the analysis of PAS-SV scores, the ASD group once again achieved the highest scores after the PD individuals, although this time the difference was not statistically significant compared to the other diagnostic groups.

Discussion: These findings highlight the central role of the autism spectrum in SAD and OCD diagnoses. They provide support for the hypotheses of a neurodevelopmental basis for social anxiety and OCD, contributing to the growing body of evidence supporting a dimensional and interconnected view of mental health conditions.

Background: Greater therapeutic alliance has been associated with an improved treatment outcome in various clinical populations. However, there is a lack of evidence for this association in posttraumatic stress disorder (PTSD) in young patients. We therefore investigated the development of the therapeutic alliance during Developmentally adapted cognitive processing therapy (D-CPT) in adolescents and young adults with PTSD following abuse to answer the question whether there was a connection between the therapeutic alliance and symptom reduction.

Methods: Weekly assessments of therapeutic alliance, rated by patients and their therapists, as well as PTSD symptom severity from a randomized controlled trial (RCT) of D-CPT were analyzed with multilevel modelling. The sample consisted of n = 39 patients aged 14-21 with a history of sexual and/or physical abuse.

Results: Therapeutic alliance increased during D-CPT. The ratings of the therapeutic alliance by patients and therapists were strongly correlated (r = .512, p < .01); however, at session level, there was a significant difference between the patients' and their therapists' alliance assessments. Patients with a higher perceived therapeutic alliance showed a greater reduction in self-reported symptoms over the course of therapy, compared to patients with lower alliance ratings. However, this only applied to the therapeutic alliance assessed by the patients.

Discussion: The therapeutic alliance plays a crucial role in D-CPT with young patients, contributing to a reduction in symptom severity over the course of treatment. It is essential that therapists prioritize the development of a strong alliance and seek feedback from their patients. The results suggest that patients' perceptions, which often differ from therapists' assessments, were more important in determining treatment success in the sample. Studies with larger samples sizes and additional independent ratings of alliance are needed to further examine the alliance-outcome link.

Trial registration: The trial was registered at the German Clinical Trial Registry, DRKS00004787, 18 March 2013, https://www.drks.de/DRKS00004787 .

Background: Non-suicidal self-injury (NSSI) is an intentional act that results in physical damage to one's body, without the intent to commit suicide. In recent years, self-injurious behaviors, including non-suicidal self-injury (NSSI), have increased, especially among adolescents and young adults. The objective of this study was to investigate the motives for NSSI among adolescents with psychiatric disorders.

Methods: Adolescents aged 12 to 18 years including patients admitted to the Department of Child and Adolescent Psychiatry at a state hospital in Babol (northern Iran) and outpatients referring to this center were included in the research. Data collection occurred between February 2021 and September 2021 from a sample of 140 participants. All subjects were given a demographic questionnaire and an inventory of statements about self-injury (Klonsky and Glenn). Moreover, a structured interview was conducted with all to diagnose the nature of the underlying disorder by a child and adolescent psychiatrist.

Results: A total of 140 adolescents with mean age 16.25 ± 1.48 years were assessed. Eighty-five (60.7%) of them were girls. Sixty-five (46.4%) individuals were inpatients and 75 (53.6%) were outpatients; 78 (55.8%) had a history of NSSI and 62 (44.2%) cases had no history of self-injury. The most common method of self-injury was Wounding or cutting a part of the body (n = 56(40.0%)). Attention-deficit/hyperactivity disorder (ADHD) emerged as the most common psychiatric diagnosis among individuals with a history of NSSI. Emotion regulation was the most common motive for self-injury (p = 0.004). The prevalence of self-injury was higher among adolescent girls (p = 0.049). There was no significant relationship between self-injury and inpatient or outpatient status (p = 0.342).

Conclusions: Our findings indicate that NSSI in adolescents is not limited to a specific or single motive; instead, multiple factors contribute to its occurrence. NSSI methods can also vary, and all should be considered when examining this behavior.

Background: Few new psychiatric drugs have entered the market in recent decades; in contrast, the number of drugs carrying pharmacogenomic labels continues to increase. For the foreseeable future, the advancement of psychiatry and drug therapy may hinge on personalized treatment. Currently, antipsychotic or antidepressant choices rely heavily on the clinical experience of psychiatrists and potentially lengthy iterative trials. During these trials, the clinical response to treatment in acutely depressed patients can be assessed only after several weeks of exposure to the drug. Although pharmacogenomic testing has been used in clinical care for several years, most Chinese clinicians struggle to utilize the information accurately, resulting in expensive tests that provide little real benefit to patients. Here, we demonstrate how to combine the results of pharmacogenomic testing to develop an individualized treatment plan. Our goal is to find the optimal medication regimen and dosage for the patient in the shortest possible time, control symptoms as soon as possible, and predict adverse drug reactions. This approach aims to offer a practical therapeutic idea for clinical practice.

Case presentation: We present the case of a 27-year-old female patient experiencing a relapse of depression. Despite previous attempts with empiric medication, her symptoms remained uncontrolled, leading to exacerbation and drug withdrawal reactions. Utilizing the results of pharmacogenetic testing, we crafted an individualized treatment plan, resulting in rapid remission without any adverse drug reactions.

Conclusion: Recognizing the complexity of antidepressant response, our patients aim to improve their understanding, as well as that of other healthcare providers, by undergoing pharmacogenomics testing. This enhances the credibility of their medication choices. While pharmacogenomics is just one aspect considered in selecting a treatment regimen for depression, it remains a valuable tool for increasing credibility and mitigating potential adverse events.

Background: Mental disorders are increasingly prevalent, leading to increased medical expenditures. To refine the reimbursement of medical costs for inpatients with mental disorders by health insurance, an accurate prediction model is essential. Per-diem payment is a common internationally implemented payment method for medical insurance of inpatients with mental disorders, necessitating the exploration of advanced machine learning methods for predicting the average daily hospitalization costs (ADHC) based on the characteristics of inpatients with mental disorders.

Methods: We used data including demographic information, clinical/functional characteristics, institutional features, and cost information of 5070 hospitalized patients with mental disorders in Jinhua, China, and employed six algorithms to predict ADHC. Performance of these six algorithms was evaluated through 5- old cross-validation combined with bootstrap method to select the most suitable algorithm and identify key factors influencing ADHC.

Results: The random forest (RF) model demonstrated better performance (R-squared (R²) = 0.6417 (95% CI, 0.6236-0.6611), root-mean-square error (RMSE) = 0.2398 (95% CI, 0.2252-0.2553), mean-absolute error (MAE) = 0.1677 (95% CI, 0.1626-0.1735), mean-absolute-percentage error (MAPE) = 0.0295 (95% CI, 0.0287-0.0304)). According to feature importance ranking, models incorporating top 11 factors (> 0.01) demonstrated comparable performance to those encompassing all variables. Top four factors (> 0.05) were level of medical institution, age, functional classification, and cognitive classification. Notably, level of medical institutions was the most significant factor across all primary models. Higher medical institutions level, patients below 20 and above 75 years old, lower functional classification, and lower cognitive classification are associated with increased ADHC.

Conclusions: Machine learning algorithms, particularly RF algorithm, enhance accuracy of predicting ADHC for mental health patients. The findings of this study provide evidence for setting up more reasonable insurance payment standards for inpatients with mental disorders and support resource allocation in clinical practice.

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

Case presentation: We report a case of a 48-year-old Japanese male with epilepsy-associated psychosis and mild intellectual disability who experienced severe EPS during a gradual cross-titration from risperidone to paliperidone while on valproate therapy. The patient had a history of well-controlled epilepsy with valproate and developed auditory hallucinations, delusions, and psychomotor agitation at age 48. Initial treatment with risperidone was partially effective but did not sufficiently manage his psychotic symptoms, prompting a switch to paliperidone. Shortly after increasing the paliperidone dose, the patient developed significant EPS, including muscle rigidity and elevated creatine kinase levels, indicative of potential neuroleptic malignant syndrome. Paliperidone was immediately discontinued, leading to a marked improvement in symptoms.

Discussion: This case highlights the pharmacokinetic interaction between valproate and paliperidone, which can elevate plasma levels of paliperidone and exacerbate EPS. Literature suggests that valproate can prolong the gastrointestinal retention time of paliperidone, leading to increased absorption and enhanced dopaminergic blockade. The gradual cross-titration method may have compounded these effects, emphasizing the need for careful dose adjustments and monitoring during antipsychotic switching, especially in patients on concomitant valproate therapy.

Conclusion: The findings suggest that direct substitution methods, rather than gradual cross-titration, may be safer when switching from risperidone to paliperidone, particularly in patients receiving valproate. Clinicians should be aware of the potential interactions and closely monitor for signs of EPS during such therapy adjustments.

Background: The Dissociative Experiences Scale (DES-II) is widely used globally. However, psychometric properties of the scale have not been adequately examined. The present study aimed to examine the psychometric properties and longitudinal stability of the DES-II.

Method: We collected data at two time points, approximately three and a half years apart. At Time 1 (T1), 1029 participants (515 females, 514 males) with a mean age of 44.64 (± 14.02) responded to the survey. Out of the T1 participants, 210 individuals (105 females, 105 males) also responded to the T2 survey. We conducted item parameters of the DES-II with item response theory (IRT).

Results: Our results showed that the DES-II is suitable for measuring strong dissociative traits, with all items displaying high discriminative power. The cut-off points for the DES-II were within a good range of measurement accuracy, and longitudinal stability over approximately three and a half years was adequate.

Conclusion: In the present study, we applied item response theory (IRT) to the DES-II, which has traditionally been interpreted using classical test theory (CTT). Results suggested the need for item-focused assessment rather than relying solely on mean scores or cut-off points. Specifically, results suggested that the severity levels differed across item ratings, and to set cut-off points for each item based on the severity of the ratings. Furthermore, the possibility of cultural differences in response patterns of the DES-II was indicated. However, few studies have discussed cultural differences based on IRT; hence, further research should examine response patterns of the DES-II across various cultures. In conclusion, the DES-II is a valuable tool for assessing dissociative symptoms, with adequate psychometric properties from an item response theory perspective. Clinicians should consider item-specific responses in their assessments, and further research is needed to explore the scale's applicability across diverse populations.